Roivant Sciences Ltd’s filing revealed that its Officer Venker Eric acquired Company’s shares for reported $4.38 million on Jan 12 ’26. In the deal valued at $21.92 per share,200,000 shares were bought.
Then, Sukhatme Mayukh sold 1,018,995 shares, generating $22,122,381 in total proceeds. Upon selling the shares at $21.71, the President & CIO now owns 20,267,429 shares.
Before that, Sukhatme Mayukh sold 311,873 shares. Roivant Sciences Ltd shares valued at $6,780,119 were divested by the President & CIO at a price of $21.74 per share. As a result of the transaction, Sukhatme Mayukh now holds 19,273,032 shares, worth roughly $427.09 million.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 0.82% to $22.16. Over the last five days, the stock has gained 4.04%. Roivant Sciences Ltd shares have risen nearly 101.09% since the year began. Nevertheless, the stocks have risen 2.12% over the past one year.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-12-31, dropping by -1.33 million shares to a total of 19.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 20.91 million shares. There was a decline of -6.82%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
